{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:32:41Z","timestamp":1793035961600,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,5,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed\/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) in initial analyses of one of three cohorts from the CheckMate 205 study of nivolumab for cHL. Here, we assess safety and efficacy after extended follow-up of all three cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, single-arm, phase II study enrolled patients with relapsed\/refractory cHL after auto-HCT treatment failure into cohorts by treatment history: brentuximab vedotin (BV)\u2013na\u00efve (cohort A), BV received after auto-HCT (cohort B), and BV received before and\/or after auto-HCT (cohort C). All patients received nivolumab 3 mg\/kg every 2 weeks until disease progression\/unacceptable toxicity. The primary end point was objective response rate per independent radiology review committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 243 patients were treated; 63 in cohort A, 80 in cohort B, and 100 in cohort C. After a median follow-up of 18 months, 40% continued to receive treatment. The objective response rate was 69% (95% CI, 63% to 75%) overall and 65% to 73% in each cohort. Overall, the median duration of response was 16.6 months (95% CI, 13.2 to 20.3 months), and median progression-free survival was 14.7 months (95% CI, 11.3 to 18.5 months). Of 70 patients treated past conventional disease progression, 61% of those evaluable had stable or further reduced target tumor burdens. The most common grade 3 to 4 drug-related adverse events were lipase increases (5%), neutropenia (3%), and ALT increases (3%). Twenty-nine deaths occurred; none were considered treatment related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With extended follow-up, responses to nivolumab were frequent and durable. Nivolumab seems to be associated with a favorable safety profile and long-term benefits across a broad spectrum of patients with relapsed\/refractory cHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2017.76.0793","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T15:57:31Z","timestamp":1522166251000},"page":"1428-1439","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":647,"title":["Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial"],"prefix":"10.1200","volume":"36","author":[{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Paul","family":"De Boer","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Kato","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sumbul","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Farsaci","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; John M. Timmerman, University of California..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.854888"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.326"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519009"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12143"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034348"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1588"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx097"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.028"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.011"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.080895"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13441"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385"}],"updated-by":[{"DOI":"10.1200\/jco.2018.79.3547","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.76.0793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:38:48Z","timestamp":1653802728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.76.0793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,5,10]]}},"alternative-id":["10.1200\/JCO.2017.76.0793"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.76.0793","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732912577.793581850","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"2018-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}